Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters

Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial

(2010) Desirée Rosa Cavalcanti et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials

(2009) D. Ziegler et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Diagnosis and treatment of multiple sclerosis

(2008) Kjell-Morten Myhr   ACTA NEUROLOGICA SCANDINAVICA

Disease-Modifying Agents for Multiple Sclerosis

(2008) Til Menge et al.   DRUGS

Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study

(2008) Mario Carbone et al.   EUROPEAN JOURNAL OF PAIN

Emerging oral drugs for multiple sclerosis

(2008) Claudio Gasperini et al.   EXPERT OPINION ON EMERGING DRUGS

Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells

(2008) Sonemany Salinthone et al.   JOURNAL OF NEUROIMMUNOLOGY

Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study

(2008) P. LÓPEZ-JORNET et al.   JOURNAL OF ORAL REHABILITATION

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Retracted: Alpha-lipoic acid supplementation and diabetes

(2008) Uma Singh et al.   NUTRITION REVIEWS